Morningstar Gives AJJ 4 Stars — 75% 3Y Revenue Growth

SG Visual Research
03-31
$AJJ Medtech(584.SI)$  

One chart on AJJ Medtech (SGX: 584).

Morningstar’s quantitative model currently shows 4-Star, ~32% undervaluation, 75%

3Y revenue growth, and a Small Growth classification.

For a micro-cap name, the key point is that AJJ is starting to show up on the market’s

small-growth medtech radar.

@Tiger_SG @新加坡交易所集团 @Daily_Discussion 


US-Iran Conflict | Hormuz Blocked Again, Can Trump Meeting Help Sustain Market Momentum?
Trump said he is willing to meet senior Iranian leaders if talks make a “breakthrough,” while a U.S. delegation including JD Vance was reported to be heading to Islamabad on April 20. At the same time, Reuters reported shipping through Hormuz was near a standstill, with only three vessel crossings in 12 hours, and broader markets opened under pressure as oil jumped. So which signal matters more now — diplomacy restarting, or the fact that the world’s key oil chokepoint is still barely moving? Is this 4% oil spike just headline panic, or the start of a deeper risk-off move for equities?
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment